Johnson & Johnson is preparing to potentially sell its orthopedics unit, DePuy Synthes, as part of plans to separate the business. The company acquired DePuy Synthes for $21.3 billion in 2011. The separation of the Orthopedics business is expected to be completed within 18 to 24 months.

CFO Joseph Wolk mentioned that Johnson & Johnson is open to various options for the split, including a sale or spinoff. Bank of America analysts believe that the move makes sense and will benefit DePuy Synthes in the long run. Buyout firms have shown interest, with the unit estimated to be worth $20-$28 billion.

Potential buyers are set to meet with Johnson & Johnson in the coming weeks. Private equity firms are considering joint bids for the unit. DePuy Synthes, known for hip and knee replacement devices, generated $9.3 billion in annual sales. Discussions are ongoing, and a transaction is not guaranteed.

In the fourth quarter of 2025, Johnson & Johnson reported adjusted earnings of $2.46 per share, up 20.6% year over year, beating expectations. The company anticipates 2026 sales to be between $99.50 billion and $100.5 billion, exceeding the consensus estimate.

Read more at Yahoo Finance: J&J Eyes Mega Sale Of DePuy Synthes In Orthopedics Breakup Push